Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: gout flare

Another Way: RheumMadness 2022 DECT in Gout Scouting Report

MedStar Georgetown Washington Hospital Center: Leen Al Saleh, MD; Ajita Acharya, MD; Elena Obreja, MD; & Akrithi U. Garren, MD  |  

Research has found dual-energy computed tomography (DECT) may be a non-invasive and cost-effective option to help rheumatologists more accurately diagnose gout.

Gout Management Recommendations from the ACR’s 2020 Guideline

  |  

The 2020 ACR Guideline for the Management of Gout is intended to provide guidance for the management of patients with gout, and includes recommendations on the indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations.1 The guideline includes 42 recommendations, of which 16 are strong….

Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi

Mary Choy, PharmD, BCGP, FASHP  |  

Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…

Prokopenko Oleg / shutterstock.com

Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

  |  

A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (metho­trexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…

Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy

  |  

A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Puja Khanna, Dinesh Khanna, Gary Cutter, Jeffrey Foster, Joshua Melnick, Sara Jaafar, Stephanie Biggers, AKM Rahman, Hui-Chen Kuo, Michelle Feese and Kenneth Saag  |  

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.